Immune globulin - Takeda
Alternative Names: 10% HyQ; 20% SubQ; CUVITRU; Cuvitru; Gammagard Liquid; Gammagard S/D; Human Immune Globulin for Subcutaneous Administration; HyQ; HYQVIA; HyQvia; Ig20Gly; IGI 10% with rHuPH20; IGIV - Baxalta; IGSC - Baxalta; immune globulin intravenous; IVIG 10%; Kiovig; SCIG 20%; SHP-671; TAK 771; TAK-339; TAK-664; TAK-881Latest Information Update: 03 Jun 2025
At a glance
- Originator Baxter International
- Developer Baxter International; Halozyme Therapeutics; Shire; Takeda
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allotransplant rejection; Chronic lymphocytic leukaemia; Guillain-Barre syndrome; HIV infections; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Multifocal motor neuropathy
- Registered Agammaglobulinaemia; Chronic inflammatory demyelinating polyradiculoneuropathy
- Phase II Ataxia
- Discontinued Alzheimer's disease
Most Recent Events
- 20 May 2025 Takeda plans a phase III trial for Multiple Myeloma (IV, Infusion) (NCT06980480)
- 06 May 2025 Takeda initiates enrollment in a phase III trial for Chronic inflammatory demyelinating polyradiculoneuropathy in USA (SC, Infusion) (NCT06747351) (EudraCT2024-517450-95-00)
- 02 May 2025 Takeda starts expanded Access for Immune globulin for Primary-immunodeficiency-diseases (In Children, In Adolescents, In adults, In the elderly) in USA (SC)(NCT06955793)